(Pre-)Clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor

Oncologist

Volumn 15, Issue 6, 2010, Pages 539-547

  Hamberg, Paul ^a   Verweij, Jaap ^a   Sleijfer, Stefan ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Angiogenesis; Pazopanib; Renal cell cancer; Tyrosine kinase inhibitor

Indexed keywords

LAPATINIB; PACLITAXEL; PAZOPANIB; PLACEBO; SORAFENIB; SUNITINIB; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS INHIBITOR; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ALOPECIA; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BLEEDING; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER INHIBITION; CELL PROLIFERATION; CLINICAL TRIAL; DIARRHEA; DISEASE MODEL; DIZZINESS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG TOLERABILITY; DYSGEUSIA; ENDOTHELIUM CELL; FATIGUE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; GILBERT DISEASE; HAIR DISCOLORATION; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; HYPOCALCEMIA; HYPOGLYCEMIA; HYPOPHOSPHATEMIA; HYPOPIGMENTATION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOCYTOPENIA; MAXIMUM PLASMA CONCENTRATION; MELANOMA; MONOTHERAPY; MOTOR DYSFUNCTION; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; PANCREAS CANCER; PHARMACODYNAMICS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; PROTEINURIA; RECOMMENDED DRUG DOSE; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISCOLORATION; SKIN TOXICITY; SOFT TISSUE SARCOMA; THROMBOCYTOPENIA; THYROID CANCER; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR XENOGRAFT; UROGENITAL TRACT TUMOR; VOMITING; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE FREE SURVIVAL; METABOLISM; NEOPLASMS; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; DISEASE-FREE SURVIVAL; HUMANS; NEOPLASMS; PYRIMIDINES; SULFONAMIDES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 77954987954     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0274     Document Type: Article

References (37)

1. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-410.
2. Foekens JA, Peters HA, Grebenchtchikov N et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 2001;61:5407-5414.
3. Toi M, Matsumoto T, Bando H. Vascular endothelial growth factor: Its prognostic, predictive, and therapeutic implications. Lancet Oncol 2001;2:667-673.
4. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-65.
5. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550.
6. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-124.
7. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-2676.
8. Kumar R, Knick VB, Rudolph SK et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007;6:2012-2021.
9. Mendel DB, Laird AD, Xin X et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-337.
10. Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-7109.
11. Sonpavde G, Hutson TE. Pazopanib: A novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep 2007;9:115-119.
12. Podar K, Tonon G, Sattler M et al. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci U S A 2006;103:19478-19483.
13. Hurwitz HI, Dowlati A, Saini S et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 2009;15:4220-4227.
14. Yau CC, Chen PJ, Curtis CM et al. Phase I study of pazopanib in hepatocellular carcinoma: Evaluation of clinical activity, pharmacokinetics and dynamic contrast enhanced MRI (DCE MRI). Eur J Cancer 2009;7(suppl 2):122.
15. De Jonge M, Savage S, Verweij J et al. A phase I open-label study of the safety and pharmacokinetics of pazopanib and lapatinib administered concurrently [abstract 3088]. Proc Am Soc Clin Oncol 2006;24:142.
16. Tan AR, Jones SF, Dowlati A et al. Phase I study of the safety, tolerability, and pharmacokinetics (PK) of weekly paclitaxel administered in combination with pazopanib (GW786034) [abstract 3552]. Proc Am Soc Clin Oncol 2008;26:166.
17. Faivre S, Delbaldo C, Vera K et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24:25-35.
18. Strumberg D, Richly H, Hilger RA et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23:965-972.
19. Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol 2010;28:1061-1068.
20. Hutson TE, Davis ID, Machiels JP et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol 2010;28:475-480.
21. Sleijfer S, Ray-Coquard I, Papai Z et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma:Aphase II study from the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC study 62043). J Clin Oncol 2009;27:3126-3132.
22. Van Glabbeke M, Verweij J, Judson I et al.; EORTC Soft Tissue and Bone Sarcoma Group. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002;38:543-549.
23. Friedlander M, Hancock KC, Benigno B et al. Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: Final results of a phase II study. Ann Oncol 2008;19(suppl 8):viii211.
24. Altorki N, Heymach J, Guarino M et al. Phase II study of pazopanib (GW786034) given preoperatively in stage I-II non-small cell lung cancer (NSCLC): A proof-of-concept study. Ann Oncol 2008;19(suppl 8):viii89.
25. Slamon D, Gomez H, Kabbinawar F et al. Randomized study of pazopanib + lapatinib vs. lapatinib alone in patients with HER2 positive advanced or metastatic breast cancer [abstract 1016]. Proc Am Soc Clin Oncol 2008;26:45.
26. Prince HM, Hönemann D, Spencer A et al. Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: A phase 2 study of pazopanib (GW786034). Blood 2009;113:4819-4820.
27. Routhouska S, Gilliam AC, Mirmirani P. Hair depigmentation during chemotherapy with a class III/V receptor tyrosine kinase inhibitor. Arch Dermatol 2006;142:477-479.
28. Xu CF, Reck BH, Xue Z et al. Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism. Eur J Cancer 2009;7(suppl 2):119.
29. Motzer RJ, Mazumdar M, Bacik J et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17:2530-2540.
30. Escudier B, Szczylik C, Hutson TE et al. Randomized phase II trial of firstline treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:1280-1289.
31. Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584-3590.
32. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 2007;370:2103-2111.
33. Rini BI, Halabi S, Rosenberg JE et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008;26:5422-5428.
34. Thompson Coon JS, Liu Z, Hoyle M et al. Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: A systematic review and indirect comparison of clinical effectiveness. Br J Cancer 2009;101: 238-243.
35. Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516-2524.
36. Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24.
37. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-134.